Inhibrx (INBX) Director Jon Kayyem Buys 5,000 Shares

What Happened
Director Jon Faiz Kayyem reported a purchase of 5,000 Inhibrx (INBX) common shares on 2026-09-23 at $100.00 per share, for a total transaction value of $500,000. The Form 4 lists the transaction type as a purchase (code P), described as an open-market or private purchase.

Key Details

• Transaction date and price: 2026-09-23 at $100.00 per share.
• Shares acquired and value: 5,000 shares; total $500,000.
• Filing date / timeliness: Form 4 filed with the SEC on 2026-09-23 (same day as the transaction).
• Shares owned after transaction: Not specified in the information provided in this summary.
• Footnotes: F1–F5 indicate these securities are held directly by family trusts and custodial accounts (The Jon F. Kayyem and Paige Gates‑Kayyem Family Trust; Jon Faiz Kayyem Revocable Trust; Paige‑Gates Kayyem Revocable Trust; and custodial accounts for two minor children). The reporting person is trustee for certain trusts and disclaims beneficial ownership of some accounts except for any indirect pecuniary interest.
• No options/exercises, no 10b5‑1 plan or tax‑withholding event is noted in the provided details.

Context
Purchases by insiders can be interpreted by retail investors as a more informative signal than routine sales, but filings that show ownership via trusts or custodial accounts can reflect estate-planning or family arrangements rather than a personal investment decision. The P code here means the Form 4 reported a purchase but does not by itself distinguish between an open‑market buy or a private transaction.